Novarna — Complex medicine, simple by design

How to move forward with Novarna.

Pharma and research partners. Academic labs. One clear path to working with Novarna.

Who we work with

Novarna works with pharma, biotech, and academic research partners.

Pharma partners

Large pharma and biotech companies with defined RNA therapeutic programs

Access NovaEngine™ directly for custom RNA design programs against your defined targets. We generate novel candidates, validate in NovaLab™, and deliver optimized leads on a milestone-aligned engagement structure. From a 16-week pilot to a multi-year co-development partnership.

Engagement: T1 Rapid Discovery · T2 Optimized Lead · T3 Discovery Partnership
Academic research partners

Research labs and academic institutions with validated biological targets

Novarna’s platform was built in academic partnership — our first validated PoC came from a collaboration with the University of Michigan DiFeo Lab. We work with academic groups to design against specific targets, validate in a shared workflow, and co-develop IP toward clinical or commercial translation.

Engagement: Joint research · IP co-development · Pathway to preclinical
Pharma & research partner engagement

Three engagement tiers. Scoped to your program, your timeline, and your budget.

Every partner engagement starts with a confidential conversation about your target and program goals. From there, we scope an engagement that fits — from a focused proof-of-concept pilot to a multi-year co-development relationship.

T1
Rapid Discovery
A focused pilot targeting a specific RNA or protein of interest. Ideal for proof-of-concept validation and platform assessment with your team.
  • Target definition session with NovaLab science team
  • AI-generated candidate library against defined target
  • Wet lab synthesis and preliminary screening
  • Ranked candidate report with design rationale
T2
Optimized Lead
Extended design and validation cycles delivering optimized, preclinical-ready candidates against a defined target — with data packages for regulatory and clinical planning.
  • All T1 deliverables plus iterative optimization rounds
  • Multi-objective optimization: affinity, specificity, stability
  • In vitro efficacy validation in relevant cell models
  • Preclinical candidate data package
T3
Discovery Partnership
Multi-year co-development relationships with milestone and royalty structures that align incentives from discovery through commercialization. Priority engine access included.
  • Multi-target programs across disease areas
  • Cross-program learning — AI improves across your portfolio
  • Priority NovaEngine access and dedicated research capacity
  • Milestone + royalty structure aligned to commercialization

All engagements begin with a confidential, no-commitment conversation. We evaluate target fit, scope a program together, and only proceed when we’re confident the platform is the right tool for your program. Typical time from first conversation to T1 pilot launch: 6–8 weeks.

Academic partnerships

Our science was built in academic partnership. It still is.

Novarna’s first validated proof-of-concept came from a research collaboration with an academic lab — not a proprietary internal program. We believe the most rigorous validation happens when our designs are tested by independent scientists in independent assays.

Oncology research
University of Michigan — DiFeo Lab
Validated AI-designed circRNA sponge sequences targeting miR-181a in ovarian cancer models. Novarna designs outperformed commercially available anti-miR antagonists — wet lab confirmed.

Ready to move forward?

The RNA design space is moving fast. The window for first-mover partnerships and seed investment is open now — and Novarna is the only platform positioned to fill it.